Rizatriptan Benzoate Tablet
Product Images NDC 51407-682

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 51407-682). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

51407-681-12 Ct (pl).jpg (51407 681 12 Ct (pl))

51407-681-12 Ct (pl).jpg (51407 681 12 Ct (pl))
FDA Label Image

51407-682-12 Ct (pl).jpg (51407 682 12 Ct (pl))

51407-682-12 Ct (pl).jpg (51407 682 12 Ct (pl))
FDA Label Image

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)
The text provides a graph (Figure 1) showing the estimated probability of achieving an initial headache response within 2 hours after treatment with rizatriptan benzoate or placebo. The graph includes data from four placebo-controlled outpatient trials (Studies 1, 2, 3, and 4). The graph displays the probabilities over time and includes different treatment options: placebo, rizatriptan benzoate 5 mg, and rizatriptan benzoate 10 mg. The averages displayed on the graph are based on pooled data from these trials. The graph is a Kaplan-Meier plot, with the x-axis representing hours post-dose and the y-axis representing the probability of achieving headache response.*
FDA Label Image

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Po (Rizatriptan Fig2)

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Po (Rizatriptan Fig2)
Figure 2 depicts the estimated probability of patients taking a second dose of Rizatriptan Benzoate tablets or other medication for migraines over a 24-hour period following the initial dose of study treatment. The data used in this analysis were obtained from pooled studies 1, 2, 3, and 4. The table within the figure provides the percentage of patients who took a second dose at different time intervals. The Kaplan-Meier plot includes patients who had a headache response at 2 hours and those who had no response to the initial dose. It should be noted that remedication within 2 hours post-dose was not allowed and patients not using additional treatments were censored at 24 hours. This analysis aims to provide valuable insights into the likelihood of patients requiring a second dose of medication for migraines.*
FDA Label Image

Figure3 (Rizatriptan Fig3)

Figure3 (Rizatriptan Fig3)
FDA Label Image

Chemical Structure (Rizatriptan Str)

Chemical Structure (Rizatriptan Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.